Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Monte Rosa Therapeutics (GLUE) Other Operating Expenses: 2022-2024

Historic Other Operating Expenses for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Dec 2024 value amounting to -$29.6 million.

  • Monte Rosa Therapeutics' Other Operating Expenses fell 15.01% to -$8.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$24.1 million, marking a year-over-year change of. This contributed to the annual value of -$29.6 million for FY2024, which is 123562.50% down from last year.
  • As of FY2024, Monte Rosa Therapeutics' Other Operating Expenses stood at -$29.6 million, which was down 123,562.50% from $24,000 recorded in FY2023.
  • Monte Rosa Therapeutics' 5-year Other Operating Expenses high stood at $109,000 for FY2022, and its period low was -$29.6 million during FY2024.
  • For the 3-year period, Monte Rosa Therapeutics' Other Operating Expenses averaged around -$9.8 million, with its median value being $24,000 (2023).
  • Data for Monte Rosa Therapeutics' Other Operating Expenses shows a maximum YoY slumped of 123,562.50% (in 2024) over the last 5 years.
  • Over the past 3 years, Monte Rosa Therapeutics' Other Operating Expenses (Yearly) stood at $109,000 in 2022, then tumbled by 77.98% to $24,000 in 2023, then slumped by 123,562.50% to -$29.6 million in 2024.